<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414397</url>
  </required_header>
  <id_info>
    <org_study_id>1878-702-008</org_study_id>
    <nct_id>NCT04414397</nct_id>
  </id_info>
  <brief_title>A Study Evaluating JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old</brief_title>
  <official_title>A Multicenter, Evaluator-blinded, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma&#xD;
      XC injectable gel in adult participants seeking correction of temple hollowing&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with at Least a 1-Point Improvement (Decrease) in Temple as Assessed by the Evaluating Investigator (EI) using the Allergan Temple Hollowing Scale (ATHS)</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants \&quot;Improved\&quot; or \&quot;Much Improved\&quot; as assessed by the Evaluating Investigator using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and-2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants \&quot;Improved\&quot; or \&quot;Much Improved\&quot; as self-assessed by participant using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Participant will assess temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and-2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on FACE-Q Satisfaction with Facial Appearance questionnaire at Month 3</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>10-item questionnaire assessing satisfaction with various aspects of facial appearance. Participants respond to each item as: 1 Very Dissatisfied, 2 Somewhat Dissatisfied, 3 Somewhat Satisfied, 4 Very Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 3 on participants responses on FACE-Q Satisfaction with Temples questionnaire</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>Multiple item questionnaire assessing satisfaction with various aspects of the temples. Participants respond to each item as: 1 Very Dissatisfied, 2 Somewhat Dissatisfied, 3 Somewhat Satisfied, 4 Very Satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Temple Hollowing</condition>
  <arm_group>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control- No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment is administered. Optional treatment at month 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLUMA® XC</intervention_name>
    <description>JUVÉDERM VOLUMA® XC injectable gel</description>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants in general good health&#xD;
&#xD;
          -  Participants seeking improvement of temple hollowing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Temple hollowing due to trauma, congenital malformations, or lipodystrophy, either&#xD;
             congenital or acquired&#xD;
&#xD;
          -  Experienced trauma to the temple area within 6 months before enrollment or has&#xD;
             residual deficiencies, deformities, or scarring&#xD;
&#xD;
          -  Temporal arteritis or history of temporal arteritis&#xD;
&#xD;
          -  Temporomandibular joint dysfunction or any other jaw issues&#xD;
&#xD;
          -  Recurrent temporal headaches such as temporal tendinitis migraine&#xD;
&#xD;
          -  Active or recurrent inflammation or infection in either eye&#xD;
&#xD;
          -  Tendency to develop hypertrophic scarring&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA&#xD;
             products, or Streptococcal protein&#xD;
&#xD;
          -  Current cutaneous or mucosal inflammatory or infectious processes (e.g. acne, herpes),&#xD;
             abscess, an unhealed wound, or a cancerous or precancerous lesion, above the subnasal&#xD;
&#xD;
          -  History of detached retina, retinal vascular occlusion (eg, vein or arterial&#xD;
             occlusion), narrow angle glaucoma, neovascular eye disease, or severely&#xD;
             impaired/absent eye function in 1 or both eyes&#xD;
&#xD;
          -  Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on&#xD;
             the temple area (eg, biopsy)&#xD;
&#xD;
          -  Fat injection or permanent facial implants anywhere in the face&#xD;
&#xD;
          -  Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months&#xD;
             before enrollment&#xD;
&#xD;
          -  Temporary dermal filler injections above the subnasale within 24 months before&#xD;
             enrollment&#xD;
&#xD;
          -  Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before&#xD;
             enrollment (examples of mesotherapy or cosmetic facial procedures are face-lift,&#xD;
             laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate&#xD;
             or greater depth chemical peel, or other ablative procedures .&#xD;
&#xD;
          -  Injections in the nasolabial fold are acceptable only if done at least 3 months prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Botulinum toxin treatment above the subnasale within 6 months before enrollment&#xD;
&#xD;
          -  Has braces or other orthodontics or is planning such treatment during the study&#xD;
&#xD;
          -  Not eligible for this study if participants have begun using any new over the counter&#xD;
             or prescription oral or tropical, anti-wrinkle products above the subnasale within 30&#xD;
             days before enrollment or are planning to begin using such products during the study.&#xD;
             Participants who have been on a regimen of such products for at least 30 days are&#xD;
             eligible for the study if they intend to continue their regimen throughout the study&#xD;
&#xD;
          -  Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)&#xD;
&#xD;
          -  Has tattoos, piercings, facial hair, or scars above and including the subnasale that&#xD;
             would interfere with visual assessment of the temple&#xD;
&#xD;
          -  Females who are pregnant, nursing, or planning a pregnancy&#xD;
&#xD;
          -  Plans a significant weight change (more than 10% of body weight) during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians of Beverly Hills /ID# 232967</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin MD Medical Assoc. Inc /ID# 232956</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Fagien MD PA /ID# 232807</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Dermatologist /ID# 232822</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hevia Cosmetic Dermatology /ID# 232824</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Associates, LLP /ID# 232923</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137-3254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC /ID# 233144</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401-2712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delricht Research /ID# 233142</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Callender Center for Clinical Research /ID# 233167</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20769-9182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skincare Physicians /ID# 233054</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Williams Plastic Surgery Specialists /ID# 232789</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions /ID# 232953</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517-9901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Practice of Brian S. Biesman MD PLLC /ID# 232662</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute /ID# 232971</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at www.AllerganClinicalTrials.com.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

